ANHUI ANKE BIOTECHNOLOGY (GROUP) CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.75 CNY | +1.56% |
|
+0.10% | -4.60% |
| Mar. 28 | Anhui Anke Biotechnology Co., Ltd. Proposes Final Dividend for 2023 | CI |
| Mar. 27 | Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 3.64B 504M | Sales 2025 * | 4.24B 585M | Capitalization | 15.94B 2.2B |
|---|---|---|---|---|---|
| Net income 2024 * | 990M 137M | Net income 2025 * | 1.17B 162M | EV / Sales 2024 * | 4.57 x |
| Net Debt 2024 * | 730M 101M | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.76 x |
| P/E ratio 2024 * |
16.5
x | P/E ratio 2025 * |
13.9
x | Employees | 2,986 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.59% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.56% | ||
| 1 week | +0.10% | ||
| Current month | +0.31% | ||
| 1 month | -2.21% | ||
| 3 months | +0.62% | ||
| 6 months | -5.16% | ||
| Current year | -4.60% |
1 week
9.57
9.88
1 month
9.4610.18
Current year
7.5610.69
1 year
7.5612.29
3 years
7.3419.27
5 years
7.3419.27
10 years
2.6419.27
| Managers | Title | Age | Since |
|---|---|---|---|
Li Hua Song
CEO | Chief Executive Officer | 67 | 93-04-30 |
Xian Yu Du
CHM | Chairman | 54 | - |
Jian Ping Yao
PSD | President | 52 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hui Zhao
BRD | Director/Board Member | 50 | 07-04-08 |
Li Hua Song
CEO | Chief Executive Officer | 67 | 93-04-30 |
Li Ming Song
BRD | Director/Board Member | 62 | 03-07-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-15 | 9.75 | +1.56% | 16,141,070 |
| 24-04-12 | 9.6 | -0.83% | 8,691,998 |
| 24-04-11 | 9.68 | -0.62% | 9,667,600 |
| 24-04-10 | 9.74 | -1.12% | 9,479,197 |
| 24-04-09 | 9.85 | +1.13% | 9,183,652 |
End-of-day quote Shenzhen S.E., April 14, 2024
More quotes
Anhui Anke Biotechnology (Group) Co., Ltd is a China-based company principally engaged in the research, development, manufacture and distribution of biological products, Chinese patent drugs, chemical synthetic drugs, peptide drugs and nucleic acid detection products. The Companyâs main products include recombinant human interferon alfa-2b series, recombinant human growth hormone, peptides Active Pharmaceutical Ingredients (APIs), customized peptides, deoxyribonucleic acid (DNA) fluorescence detection kit, silica beads extraction kit, anti-sperm antibody test kit, pain relieving ointment, amoxicillin granules and capsules, cefaclor dispersible tablets and adefovir dipivoxil tablets, among others. The Company distributes its products in domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-04-17
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
9.75
CNY
Average target price
19.54
CNY
Spread / Average Target
+100.41%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -4.60% | 2.25B | |
| -4.17% | 86.99B | |
| +4.34% | 40.68B | |
| -23.65% | 28.61B | |
| +51.27% | 24.1B | |
| -5.17% | 17.37B | |
| -32.11% | 13.72B | |
| -5.10% | 12.49B | |
| -14.39% | 12B | |
| -3.22% | 7.94B |
- Stock Market
- Equities
- 300009 Stock
